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Gastrointestinal (GI) mesenchymal tumors other than gastrointestinal stromal tumor (GIST) are rare neoplasms, but they often
enter the diﬀerential diagnosis of more common GI lesions. Some of these mesenchymal tumors in the GI tract have well
understood molecular pathologic aspects, including desmoid tumors, inﬂammatory myoﬁbroblastic tumor (IMT), clear cell
sarcoma(CCS),inﬂammatoryﬁbroid polyp(IFP),andsynovialsarcoma(SS).Molecularpathologyis fastbecominga mainstream
focus in laboratories because it aids in the precise classiﬁcation of tumors, may be prognostic, and may help predict response to
therapy. The following review is not intended as an exhaustive summary of all mesenchymal tumors that have been reported to
involvetheGItract,butinsteadwillhighlightthecurrentknowledgeofthemostimportantnon-GISTGImesenchymalneoplasms,
focusing onthose tumors with well-characterized molecular pathology and how the molecular pathologic features impact current
diagnostic, therapeutic, and prognostic standards.
1.Introduction
Gastrointestinal (GI) mesenchymal tumors are rare, and the
molecular pathology of many of these tumors is unknown or
poorly characterized. However, some mesenchymal tumors
in the GI tract have well-understood molecular pathologic
aspects. Molecular pathology is fast becoming a mainstream
focus in laboratories because it aids in the precise clas-
siﬁcation of tumors, may be prognostic, and may help
predict response to therapy. A search of the catalogue of
somatic mutations in cancer (COSMIC) database for all
mesenchymal tumors in the tubular GI tract and adjacent
soft tissues, including esophagus, stomach, small intestine,
large intestine, peritoneum, and retroperitoneum reveals
meaningful data on three tumor types: gastrointestinal
stromal tumor (GIST), inﬂammatory ﬁbroid polyp (IFP),
and desmoid tumors. Other mesenchymal tumors that occur
in or around the tubular GI tract with well-characterized
molecularpathologicfeatures includesynovial sarcoma (SS),
inﬂammatory myoﬁbroblastic tumor (IMT), and clear cell
sarcoma (CCS); these tumors are characterized by translo-
cations rather than mutations. The following paper is not
intended as an exhaustive summary of all mesenchymal
tumors that have been reported to involve the GI tract,
but instead will highlight the current knowledge of the
most important non-GIST GI mesenchymal neoplasms,
focusing on those tumors with well-characterized molecular
pathology.
2.IntraabdominalDesmoid Tumors
Intraabdominal desmoid tumors arise in the mesentery or
retroperitoneum, predominantly in young patients. Approx-
imately 10% of desmoids occur in patients with familial
adenomatous polyposis [1] as one of the extracolonic
manifestations of Gardner syndrome. Desmoids do not
metastasize, butthey often recur locally [1, 2]. The histologic
features of desmoids are quite characteristic. In particular,
these tumors show low to moderate cellularity and are
composed of uniform spindle cells with a small, distinct2 Pathology Research International
Figure 1: Photomicrograph of H&E-stained section from a
desmoid tumor. Note the moderately cellular sweeping fascicles of
bland spindle cells. The lower left inset contains a high-power pho-
tomicrograph of the same tumor to demonstrate the characteristic
pinpoint nucleoli and collagenous stroma of desmoids.
nucleolus arranged in long, sweeping fascicles (Figure 1)[ 1].
The vasculature shows small arteries with accompanying
veins and a mild perivascular lymphoid inﬁltrate. The
associated stroma is quite collagenous. Mitotic ﬁgures may
be 10/50 high power ﬁeld (HPF) or more [3, 4], but these
tumors lack other histologic features of malignancy such as
dense cellularity, cytologic atypia, or atypical mitotic ﬁgures.
Important diﬀerential diagnostic considerations include
sclerosing mesenteritis, which does not invade bowel wall [5]
and IgG4-related sclerosing disorders, which are rich in IgG4
plasma cells [6].
Most desmoid tumors arise via perturbations within
the wnt signaling pathway (Figure 2). In FAP, desmoid
tumors arise from mutations in the adenomatous polyposis
coli (APC) gene, located on chromosome 5q21-22, which
encodes a tumor suppressor protein, although its function
may be more complex than simply a tumor suppressor [7].
Inactivation of APC leads to nuclear accumulation of β-
catenin, causing increased transcription and cell prolifer-
ation [1]. Most APC mutations associated with desmoid
tumors are found 3  to codon 1400 [8, 9]. Some sporadic
desmoid tumors also arise from APC inactivation [10]b u t
most (>80%)are APC wild type withactivating mutationsof
the CTNNB1 gene, which is located on chromosome 3p22-
p21.3. CTNNB1 encodes β-catenin [11]. Mutations almost
exclusively occur at codons 41 and 45 in exon 3 of CTNNB1
[12];mutationalanalysisofCTNNB1 isusuallynotnecessary
in typical cases of desmoids tumors but can be helpful in
unusual cases as well as helpful in distinguishing recurrent
desmoid from scar. It remains to be determined whether
particular CTNNB1 mutations help predict local recurrence
after surgical resection. One report [13] found that tumors
harboring S45F mutations in exon 3 of CTNNB1 had
signiﬁcantly poorer disease-free survival compared to wild-
type tumors or codon 41 mutants, whereas another report
showed no signiﬁcant diﬀerences in recurrence-free survival
among CTNNB1 mutants but did show worse outcome
among all mutants compared to wild-type tumors [14].
Regardless ofinciting molecular event,the ﬁnal common
pathway is accumulation of β-catenin protein within the
nuclei of the tumor cells, and although most desmoids do
not require immunohistochemistry for diagnosis, nuclear
staining of with β-catenin characterizes >90% of desmoid
tumors[1].Inourexperience,β-cateninimmunohistochem-
istry is less reliable than the literature reports, particularly
in needle biopsies, and molecular testing for mutations in
the β-catenin gene may be more reliable. Immunoreactivity
with CD117 has been reported in the literature [4], but
this is generally considered an anomaly; when appropriate
titers and antigen retrieval methods are used, desmoids
show no CD117 positivity [15–18]. Although some inves-
tigators have reported response to imatinib [19], others
have found that imatinib showed the lowest response rates
in comparison to other forms of systemic therapy [20].
Furthermore, members of the PDGFR family are expressed
in the majority of desmoids, but this expression does not
correlate with response to imatinib. Since no clear target
is present on desmoid tumors, imatinib therapy is contro-
versial at best. Surgery remains the mainstay of treatment,
but surgical resection is often incomplete because of the
inﬁltrative growth of desmoid tumors, with recurrences up
to 38% [13]. In these patients, systemic therapies such
as anti-inﬂammatory, hormonal, cytotoxic chemotherapy,
and radiation are considered. In patients with FAP, surgery
such as ileal pouch procedures may trigger desmoid tumor
formation [1].
3.Inﬂammatory Myoﬁbroblastic Tumor(IMT)
IMTs are a heterogenous group of spindle cell proliferations
with admixed lymphocytes and plasma cells that tend to
occur in children and young adults. The omentum and
mesentery are the most common extra-pulmonary sites for
IMT [21, 22], and these tumors may have a more aggressive
biologicbehavior,withmorefrequentrecurrences[23].Most
IMTs harbor a heterogenous microscopic appearance and
may contain any combination of nodular fasciitis-like areas,
compact spindle cell proliferations, or paucicellular scar-like
areas, making them a challenging diagnostic entity. In all
tumors, inﬂammatory cells are a distinctive feature, and the
inﬁltrate is often rich in plasma cells (Figure 3)[ 22].
Some authorities have diﬀerentiated IMTs from reactive
pseudosarcomatous processes and other neoplasms based on
ALKimmunoreactivityorevidenceoftheALK translocation,
but many consider ALK-negative IMTs a valid diagnostic
category. Tumors with ALK rearrangements are associated
with younger age and strongly correlate with ALK protein
expression detected by immunohistochemistry in some labs,
but in other labs ALK immunohistochemistry is nearly
always negative. Cook et al. found that 12/20 (60%) of cases
expressed ALK by immunohistochemistry [24]. In fact, the
literature reports that only about half of IMT harbor an
ALK translocation, and these may behave more indolently
than their ALK-negative counterparts [23], although this
may not be the case for all ALK-rearranged tumors. For
example, a very recent series described 11 intra-abdominal
tumors characterized by epithelioid morphology, abundantPathology Research International 3
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Figure 2: Schematic of Wnt signaling pathway. In demoid tumors, mutations are usually found in the APC gene or CTNNB1 gene, which
encodes β-catenin. Regardless of the primary defect, the end result is nuclear accumulation of β-catenin, which fails to undergo cytoplasmic
degradation.
Figure 3: Photomicrograph of H&E-stained section from an in-
ﬂammatory myoﬁbroblastic tumor. The tumor is relatively cellular
and composed of a mixture of plump spindle cells and inﬂamma-
tory cells, particularly lymphocytes and plasma cells.
myxoidstroma, and frequentneutrophils[25].These tumors
demonstrated aggressive behavior with rapid local recur-
rence, death in 5, and metastasis in 2. All 11 showed nuclear
membrane or peri-nuclear ALK immunoreactivity. Nine
tumors showed ALK translocation, and 3 tested showed
ALK/RANBP2 rearrangement.
Tumors other than IMTs have been recognized to
demonstrate immunohistochemical expression of ALK, so
genetic conﬁrmation of the ALK translocation may be
needed in problematic cases. At our institution, we ﬁnd
break-apart FISH testing to be quite useful in this setting
(Figure 4). It should be noted, however, that a very recent
report of response to the ALK inhibitor crizotinib in one
Figure 4: Photomicrograph of FISH break apart probe that targets
the ALK gene. The normal chromosome (lower middle) shows a
greensignalandredsignalincloseproximity,whereasthegreenand
red signals are far apart in the left aspect of the photomicrograph,
conﬁrming 1 copy of the ALK translocation.
patient with conﬁrmed ALK translocation and no response
in an IMT without ALK rearrangement [26]p r o v i d e s
preliminary justiﬁcation for FISH testing on all suspected
IMTs. Secondary resistance tocrizotinib in an IMT with ALK
translocation (ALK/RANBP2)hasbeenrecentlydocumented
in another patient. This resistance was suspected to occur
viatheneuroblastoma-associated F1174LALK mutationthat
has been well studied in neuroblastomas as a mechanism of
resistance to some ALK inhibitors [27].
ALK perturbations in IMTs occur via fusion of the
C-terminal kinase domain of anaplastic lymphoma kinase
(ALK) gene located on 2p23. The ALK gene encodes a tyro-
sine kinase receptor that is normally only expressed in4 Pathology Research International
Table 1: Summary of various ALK fusions in IMT.
Fusion partner Chromosomal
location
ALK staining location
(Gleason 2008)
TPM3 [30] 1q22-23 Cytoplasmic
TPM4 [30] 19p13.1 Cytoplasmic
CARS [31] 11p15 Cytoplasmic
ATIC [32]2 q 3 5C y t o p l a s m i c
SEC31L1 [33]4 q 2 1 C y t o p l a s m i c
RANBP2 [34] 2q13 Nuclear membrane
CLTC [35] 17q23 Granular cytoplasmic
the developing nervous system [28]. In IMTs, the ALK
gene fusion partner is most commonly tropomyosin 3
(TPM3/ALK)o rt r o p o m y o s i n4( TPM4/ALK), leading
to constitutive activation. Other reported fusion part-
ners include CLTC, ATIC, RANBP2, CARS,a n dSEC31L1
(Table 1). ALK along with its fusion partner tends to localize
to the cytoplasm, but ALK/RANBP2 localizes to the nuclear
membrane [29]. ALK function is poorly characterized at
this time, so it is diﬃcult to postulate the exact mechanism
of oncogenesis; nevertheless, these fusions clearly lead to
a survival and growth advantage to the cells harboring the
translocation.
4.Inﬂammatory FibroidPolyp (IFP)
IFPs are most often encountered in the stomach, usually
presenting in the antrum, but are found throughout the
GI tract. IFPs tend to arise within the submucosa and
frequently extend into the overlying mucosa. These tumors
are composed of bland spindle cells that often form perivas-
cular cuﬀs( Figure 5). The tumor cells are embedded in
a distinctive, granulation-type or ﬁbromyxoid stroma with
abundantcapillary-type vessels.Characteristically,IFPsshow
a prominent eosinophilic inﬁltrate, but other inﬂammatory
cells such as lymphocytes, mast cells, plasma cells, and
histiocytes are encountered [1]. Given their gastrointestinal
location, overlapping molecular features, and characteristic
CD34 immunoreactivity, IFPs may be confused with GISTs
[17]. Importantly, IFPs do not express other GIST-speciﬁc
m a r k e r ss u c ha sK I To rD O G - 1[ 36]. A few patients with
germline PDGFRA mutations have been reported in the
literature. The reports tend to consider these patients within
thespectrum offamilial GIST,buttheypresent with a variety
of tumors including GIST, GI neuroﬁbromas, lipomas, and
IFP-like polyps, some of which demonstrate a lipomatous
stroma [12, 37, 38].
IFPsarerarebenigntumorsofuncertainhistogenesisand
were considered reactive processes, but recently, mutations
in platelet-derived growth factor receptor alpha (PDGFRA,
chromosome 4q12) were described in IFPs located in the
stomach and small bowel [39]. In the stomach, 16/23 (70%)
IFPs harbored activating mutations of PDGFRA [40]. Six of
the mutations were located in exon 12, and 10 were located
in exon 18. In the small bowel series, 33/60 (55%) harbored
mutations in PDGFRA, 31 of which were located in exon 12,
Figure 5: Photomicrograph of H&E-stained section from an
inﬂammatory ﬁbroid polyp. The lesion is moderately cellular with
concentric whorls of spindle cells around blood vessels and numer-
ous interspersed eosinophils.
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Figure 6: Schematic of platelet-derived growth factor receptor-
(PDGFR-)related signaling pathways. Mutations can lead to acti-
vation of PDGFR independent of ligand binding. Numerous
downstreampathwaysmayleadtoneoplasticadvantagessuchascell
proliferation, growth, and survival.
and2were inexon18[41].Mostofthesemutationshadbeen
previously described in GIST. Extrapolating from the GIST
literature, 41 of the 49 mutations detected in these series
havebeenshowntocauseatleastinvitroligand-independent
activation. In addition, 100% of the stomach IFPs and 95%
of small bowel IFPs showed expression of PDGFRA detected
by immunohistochemistry, leading tothe hypothesis that the
cell of origin is a PDGFRA-positive mesenchymal cell [41].
PDGFRA is a receptor tyrosine kinase that is highly
homologous to KIT [41]. Activation is normally ligand-
dependent, but activating mutations cause constitutive
activation (Figure 6). Ligand binding can cause homo-
dimerization with another PDGFRA or hetero-dimerization
with a PDGFR-beta. PDGFRA’s interaction with several
signaling pathwayssuchasRAS/MAPK,PI3K,andJAK/STATPathology Research International 5
allowsfortheacquisitionofnumeroustumorigeniccellfunc-
tions such as cell growth, migration, inhibition of apoptosis,
and angiogenesis [42] when the receptor is constantly acti-
vated. The utility of PDGFRA mutation testing to conﬁrm
the diagnosis of IFP is minimal, but it is important to realize
that not all PDGFRA-mutated mesenchymal neoplasms in
the GI tract are GISTs.
5.ClearCellSarcoma(CCS)
Primary GI CCSsare extremely rare, with only about20 total
cases reported in the literature. Age range is quite variable,
with the youngest diagnosed at age 13 years and the oldest
at 85 [43]. The small bowel is most frequently involved, but
reports of gastric, colonic, and mesenteric tumors also exist.
These tumors are often metastatic to peritoneum, lymph
nodes, or liver at presentation and are at signiﬁcant risk
for local recurrence after surgery [43]. Morphologically and
immunophenotypically, there appear to be two CCS-like
malignancies that occur in the GI tract.
The ﬁrst typeofGICCSconstitutesthosetumorsthatare
morphologically, ultrastructurally, and immunohistochem-
ically indistinguishable from CCSs of soft tissue. CCSs are
typically composed of nests and fascicles of pale spindled to
epithelioid cells, separated by delicate ﬁbrous septa, forming
a lobulated or organoid growth pattern (Figure 7). Cellular
pleomorphism is typically uncommon, and multinucleated
giant cells may be present. Nucleoli are typically prominent.
Immunohistochemically, these tumors are indistinguishable
from melanoma, being S-100 protein as well as melanocytic
m a r k e r ss u c ha sH M B - 4 5a n dM e l a n - Ap o s i t i v ei nt h e
majority of cases [43]. In the soft tissue, these tumors are
often referred to as “melanoma of soft parts,” because of
their morphologic and immunohistochemical resemblance
to malignant melanoma. Unfortunately, immunohistochem-
istry is of no help distinguishing the two malignancies,
but the characteristic growth pattern and bland cytologic
featureswith pale cytoplasmare useful cluesto thediagnosis.
As discussed below, rearrangements in the EWRS1 gene
occur in CCS, not melanoma, which can be invaluable in
separating CCS from melanoma [44].
The second tumor type encountered in the GI tract
is characterized by mostly epithelioid cells with pale cyto-
plasm without the characteristic tumor cell nesting or
compartmentalization of soft tissue CCS. Osteoclast-like
multinucleate giant cells are by deﬁnition admixed with
the tumor cells such that the tumor has been described as
“Osteoclast-richtumoroftheGItractresemblingCCSofsoft
parts.” The tumor cells reveal S-100 protein expression but
lackanyultrastructuralorimmunohistochemical evidenceof
melanocytic diﬀerentiation. Other important morphologic
diﬀerences with conventional CCS of soft tissue include
indistinct nucleoli, more mitotic activity, and prominent
cellular pleomorphism [43].
More than 90% of CCS of soft tissue are associated
with the reciprocal translocation t(12;22)(q13;q12), which
r e s u l t si nf u s i o no ft h eEWSR1 gene and the ATF1 gene. This
translocation links the N-terminal domain of EWSR1 to the
basic leucine zipper of ATF1.[ 43] Four fusion transcripts
Figure 7: Photomicrograph of H&E-stained section from a con-
ventional clear cell sarcoma. The cells are relatively bland with
variably prominent nucleoli, low mitotic activity, and pale to clear
cytoplasm. Fibrous bands illicit a compartmentalized appearance.
Table 2: Summary of various EWSR1 fusions in CCS [45, 46].
EWSR1/ATF1 transcript Relative frequency GI tract
EWSR1 exon 8/ ATF1 exon 4 common Yes
EWSR1 exon 7/ ATF1 exon 5 common No
EWSR1 exon 10/ ATF1 exon 5 uncommon No
EWSR1 exon 7 ATF1 exon 7 uncommon No
EWSR1 exon 7/ CREB1 exon 7 uncommon Yes
(Table 2) have been described in soft tissue tumors, the most
common, or type 1, is a fusion of exon 8 of EWSR1 and
exon 4 of ATF1 [45]. This translocation thus far has been
the only described EWSR1/ATF1 translocation in CCS of
the GI tract. Another EWSR1 translocation, EWSR1/CREB1,
representing the t(2;22)(q34;q12) translocation, recently has
been identiﬁed in a subset of GI and soft tissue CCS [46–48].
CREB1 and ATF1 belong to the basic leucine zipper
superfamily of basic leucine zipper transcription factors.
In normal melanocytes, CREB and ATF1 are involved
in driving melanocytic diﬀerentiation. Both EWSR1/ATF1
and EWSR1/CREB1 fusion transcripts retain the basic
leucine zipper domain, which mediates DNA binding and
dimerization. In EWSR1/ATF1 translocations, the activating
domain of EWSR1 replaces the kinase inducible domain of
ATF1, and the protein product has been shown to bind
to microphthalmia-associated transcription factor, which
in turn activates melanocyte stimulating hormone [29].
Overexpression of CREB contributes to metastatic potential
in melanoma cells and is oncogenic in myeloid lines [46].
Genotype-phenotype correlation is imperfect in these GI
tract CCS-like tumors such that either the EWSR1/ATF1
or EWSR1/CREB1 may occur in either tumor morphology
described above [46].
Due to the rarity of CCS cases occurring in the GI tract,
theﬁrst hurdleis consideringthediagnosis. RT-PCRorFISH
analyses are critical to the diagnosis of CCS, given its mor-
phologic and immunophenotypic overlap with melanoma
(Figure 8). It remains to be determined whether these6 Pathology Research International
Figure 8: Photomicrograph of FISH break apart probe that targets
the EWSR1 gene. The normalchromosome(upper middle) shows a
greensignalandred signalincloseproximity,whereasthegreenand
red signalsarefarapart intheloweraspect ofthe photomicrograph,
conﬁrming EWSR1 translocation.
S-100 protein positive tumors harboring EWSR1 transloca-
tions represent a clinical, morphologic, immunophenotype,
and genetic spectrum of one tumor [46] or are two distinct
tumors [43].
6.SynovialSarcoma(SS)
Primary GI SSs are quite uncommon. The Armed Forces
Institute of Pathology (AFIP) reported a series of 10 SSs
after undertaking a 30-year review of stomach mesenchymal
neoplasms from 3 large centers. Prior to this series, there
were 7 total reports of SS, 6 of which involved the esophagus,
1 involved the stomach, and all were biphasic. The AFIP
series found 4 males and 6 females with an age range of
29–68 years. Two of the 8 patients with adequate followup
died of their disease and two more showed local recurrence.
Most tumors form a plaque-like mucosal mass and show
uniform spindle cells in a haphazard arrangement with a
collagenous background. Calciﬁcation or osseous metaplasia
may be present. Nine of the 10 cases were of the monophasic
type with one showing a poorly diﬀerentiated round cell
component with high mitotic activity. The ﬁnal case was
biphasic, demonstrating a mixture of epithelial and spindled
components. Mitotic activity is variable and can be greater
t h a n5 0p e r1 0H P F .A l l7t u m o r st e s t e di nt h eA F I Ps e r i e s
showed the character SYT/SSX fusion transcripts (3 with
SYT/SSX1 and 4 with SYT/SSX2)[ 49].
The characteristic molecular alteration in SS is the
t(X;18)(p11;q11) translocation, which usually fuses SYT on
chromosome 18 with SSX1 or SSX2 on the X chromo-
some. Other less common fusion partners include SSX4,
also located on the X chromosome. An SYT homolog,
SS18L1, located on chromosome 20 also has been described
as a fusion partner of SSX1 in SS [50]. The functions
of these gene products are unknown, and the oncogenic
eﬀects of the SYT/SSX fusion protein are unclear. Other
genetic events may be necessary for sarcomagenesis and
other molecular alterations have been described, including
Figure 9:PhotomicrographofH&E-stained section from a leiomy-
omatous polyp. The leiomyoma is composed of bland smooth
muscle cells with eosinophilic cytoplasm. The tumor is directly
apposed to the colonic mucosa, suggesting derivation from the
muscularis mucosae.
ERBB2 expression, IGF2 upregulation, CD44 repression,
PTEN inactivation, and mutations associated with the wnt
pathway [28]. Break-apart FISH probes are invaluable at our
institution in conﬁrming the diagnosis of SS, particularly in
monophasic ﬁbrous types, but PCR-based assays are used
eﬀectively at other institutions [50].
7.SmoothMuscleTumors
Leiomyomas of the GI tract show a male predominance and
are most common in the colon and rectum, where they
actually outnumber GIST [1]. The vast majority of GI
leiomyomas are benign smooth muscle proliferations arising
from the muscularis mucosae, often giving a polypoid endo-
scopic appearance (Figure 9)[ 51]. Rarely, cytologic atypia
(“symplastic” leiomyoma) or even more rarely, mitotic
activity may occur [18]. The second most common location
for GI leiomyoma is in the distal esophagus, where they also
outnumber GIST [51]. Esophageal leiomyomas usually are
intramural in location, arising in the muscularis propria.
Esophageal leiomyomas often show undulating borders and
canrange insize from <1mmto>10cm[1]. Various Xchro-
mosomal abnormalities, including collagen type IV alpha 5
and alpha 6, have been described in esophageal leiomyomas,
which potentially accounts for the male predominance in
these neoplasms [18]. GI leiomyomas may be confused
with GISTs, and immunohistochemistry in this diﬀerential
diagnosis can be quite helpful. Leiomyomas are invariably
strongly positive for desmin, but are negative for CD117.
One must not confuse CD117-positive mast cells that may
be seen in between smooth muscles cells from true CD117
immunoreactivity in the smooth muscle cells [52].
GIleiomyosarcomasarequiterare[18,53].They aregen-
erally large masses and are characterized by cytologic atypia,
high mitotic rate, and necrosis. Extra-intestinal leiomyosar-
coma may show complex cytogenetic abnormalities [29]a n d
have been recently shown to have loss of chromosomes 10qPathology Research International 7
Figure 10:PhotomicrographofH&E-stained sectionfrom agastric
schwannoma. These tumors are often more easily recognized by
their prominent lymphoid reaction at the periphery and lack of
encapsulation rather than classic soft tissue schwannoma features
such as Verocay bodies or thick, hyalinized vessels.
and 13qalongwith ampliﬁcation of17p13.1to 11.2[54], but
the molecular pathology of GI leiomyosarcoma is unknown.
8.Schwannoma
Schwannomas are most commonlyencountered in the stom-
ach[55]butarefoundthroughouttheGItract [56,57].They
may present as polyps or intramural masses. Their histologic
appearance is often somewhat diﬀerent than their extra-
GI counterparts (Figure 10). GI schwannomas usually lack
well-developed nuclear palisading, hyalinized vessel walls, or
a capsule. Only rarely are the characteristic Antoni A and B
patterns well developed, and Verocay bodies usually are not
encountered. Distinguishing most schwannomas requires
observation of the typical “wavy” nuclei with tapered
ends; however, a minority may demonstrate an epithelioid
morphology [57]. Regardless of morphology, all tumors
demonstrate diﬀuse S-100 protein immunoreactivity while
lacking CD117 positivity. Another characteristic feature of
GI schwannomas is a prominent lymphoid inﬁltrate at the
tumor periphery. GI schwannomas are benign and do not
seem to occur in the setting of NF2 [1]. In addition, GI
schwannomas show no NF2 mutations and only rare LOH
of ch. 22q [56], which is diﬀerent than their soft tissue
counterparts. Rare examples tested for KIT mutations have
been wild type [58].
9.Mesenchymal Polyps
A variety of mesenchymal lesions present as incidentally
identiﬁed polyps during routine endoscopic procedures
(usually colonoscopy), including perineuriomas/ﬁbroblastic
polyps [59], muscularis mucosae leiomyomas [51], Schwann
cell “hamartomas,” [60], granular cell tumors [61], elastoﬁ-
bromatous polyps [62], and ganglioneuromas [63]. Colonic
perineuriomas/ﬁbroblastic polyps are often associated with
a hyperplastic polyp-like component with serrated epithe-
lial crypts. A recent study reported BRAF mutations in
Figure 11: Photomicrograph of H&E-stained section from a sub-
mucosal lipoma in the colon. The tumor is composed of mature
ﬁbroadipose tissue with sharp demarcation from the overlying
mucosa.
63% of the epithelial component of these polyps. The
authors concluded that the polyps are true mixed epithelial-
mesenchymal neoplasms, but there remains no conclusive
evidence that the spindle cell proliferation is truly neoplastic
[64]. Ganglioneuromas are benign lesions composed of
ganglion cells, nerve ﬁbers, and Schwann cells[60]t h a to f t e n
arise in the setting of inherited tumor syndromes, includ-
ing Cowden syndrome (PTEN mutations), MEN 2B, and
NF1 [60], among others. Solitary ganglioneuromas are not
considered to be a marker of an inherited syndrome. Aside
from syndrome-associated ganglioneuromas, the molecular
pathologic aspects of these benign polypoid mesenchymal
lesions are uncharacterized.
10.AdipocyticTumors
Lipomas are most common in the right colon and usually
are identiﬁed as small intramural polypoid lesions. They
are usually centered within the submucosa and composed
of mature-appearing adipocytes that are relatively uniform
in size and lack cytologic atypia (Figure 11). These lesions
are often endoscopically suspected after eliciting the “pillow
sign” with closed biopsy forceps [65]. No molecular char-
acterization of GI lipomas exists; conventional soft tissue
lipomas exhibit abnormal karyotypes in about 60% of cases,
most commonly involving rearrangement of chromosome
12q13∼15 encompassing the chromatin remodeling gene
HGMA2 [66].
Primary GI liposarcomas are exceptionally rare tumors.
Most liposarcomas that involve the gut arise within the re-
troperitoneum, and this is one of the more common
causes of a sarcoma presenting as a GI mass. Typical well-
diﬀerentiated liposarcomas are fatty tumors that demon-
strate large, atypical cells embedded within ﬁbrous septa or
between the fat cells, butothermorphologies such as inﬂam-
matory or sclerosing exist. Conventional liposarcoma may
de-diﬀerentiate and at least partially loose their typical well-
diﬀerentiated component. About 80% of well-diﬀerentiated8 Pathology Research International
liposarcomas are characterized by ring or giant marker chro-
mosomes derived from chromosome 12q13∼q15, including
MDM2,HGMA2,and othergenes[67]. Whenmore sensitive
methods such as FISH, PCR, or immunohistochemistry are
employed, >95% of tumors show MDM2 ampliﬁcation [68,
69].Therefore, assessing forampliﬁcationofMDM2by FISH
or immunohistochemistry is a powerful tool in supporting
the diagnosis liposarcoma secondarily involving the GI tract.
11.GlomusTumors
These tumors are morphologically similar to their coun-
terparts that are most commonly encountered in the distal
extremities. The vast majority of GI glomus tumors have
been documented to occur in the stomach with fewer
occurringintheintestinesand<150caseshavebeenreported
in the English literature [70]. Glomus tumors are composed
of a proliferation of sharply demarcated modiﬁed smooth
muscle cells, which are often arranged around dilated
staghorn vessels. The cells contain a round nucleus and pale
cytoplasm and generally low mitotic activity. Focal atypia
and vascular invasion reportedly are common. In the AFIP
series of 32 gastric glomus tumors, none of the 5 tumors
tested for mutations in exons 9 or 11 of the KIT gene showed
am u t a t i o n[ 70]. Otherwise, the molecular pathology of
glomus tumors is unknown.
12.Conclusion
Primary mesenchymal tumors of the GI tract are rare, but
like their soft tissue counterparts, molecular pathology often
playsacriticalroleinthework-upofthesetumors.Molecular
pathology plays a major role the diagnosis of these tumors,
particularly in clear cell sarcoma, inﬂammatory myoﬁbrob-
lastic tumor, synovial sarcoma, and liposarcoma, among
others. Powerful prognostic data also is emerging such as in
inﬂammatory myoﬁbroblastic tumor with ALK rearrange-
ments and possibly CTNNB1 mutations in desmoids. The
future of molecular pathology is in predictive molecular
testing—molecular pathology tests aimed at aiding our
clinical colleagues in selecting the best treatments for our
patients. Although personalized therapy is not standard of
care yet in these rare tumors, the recent ALK antagonist case
reports in IMTs suggest that it is only a matter of time.
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